Novel Type V-A CRISPR Effectors Are Active Nucleases with Expanded Targeting Capabilities
- PMID: 33146573
- PMCID: PMC7757703
- DOI: 10.1089/crispr.2020.0043
Novel Type V-A CRISPR Effectors Are Active Nucleases with Expanded Targeting Capabilities
Abstract
Cas12a enzymes are quickly being adopted for use in a variety of genome-editing applications. These programmable nucleases are part of adaptive microbial immune systems, the natural diversity of which has been largely unexplored. Here, we identified novel families of Type V-A CRISPR nucleases through a large-scale analysis of metagenomes collected from a variety of complex environments, and developed representatives of these systems into gene-editing platforms. The nucleases display extensive protein variation and can be programmed by a single-guide RNA with specific motifs. The majority of these enzymes are part of systems recovered from uncultivated organisms, some of which also encode a divergent Type V effector. Biochemical analysis uncovered unexpected protospacer adjacent motif diversity, indicating that these systems will facilitate a variety of genome-engineering applications. The simplicity of guide sequences and activity in human cell lines suggest utility in gene and cell therapies.
Conflict of interest statement
D.S.A.G., L.M.A., A.E.D., J.B.A., J.L., C.NB., C.T.B., and B.C.T. are employees of Metagenomi, Inc. Patent applications related to the manuscript have been filed.
Figures


Similar articles
-
Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.Biochem Soc Trans. 2020 Feb 28;48(1):207-219. doi: 10.1042/BST20190563. Biochem Soc Trans. 2020. PMID: 31872209 Free PMC article. Review.
-
Metagenome-Derived CRISPR-Cas12a Mining and Characterization.CRISPR J. 2025 Jun;8(3):189-204. doi: 10.1089/crispr.2024.0099. Epub 2025 May 21. CRISPR J. 2025. PMID: 40397663
-
Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.Methods Mol Biol. 2021;2162:185-193. doi: 10.1007/978-1-0716-0687-2_10. Methods Mol Biol. 2021. PMID: 32926383
-
The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks.BioDrugs. 2019 Oct;33(5):503-513. doi: 10.1007/s40259-019-00369-y. BioDrugs. 2019. PMID: 31385197 Review.
-
ErCas12a CRISPR-MAD7 for Model Generation in Human Cells, Mice, and Rats.CRISPR J. 2020 Apr;3(2):97-108. doi: 10.1089/crispr.2019.0068. CRISPR J. 2020. PMID: 32315227 Free PMC article.
Cited by
-
Recent advances in CRISPR-based single-nucleotide fidelity diagnostics.Commun Med (Lond). 2025 Jul 1;5(1):252. doi: 10.1038/s43856-025-00933-4. Commun Med (Lond). 2025. PMID: 40593148 Free PMC article. Review.
-
Characterization of Cme and Yme thermostable Cas12a orthologs.Commun Biol. 2022 Apr 6;5(1):325. doi: 10.1038/s42003-022-03275-2. Commun Biol. 2022. PMID: 35388146 Free PMC article.
-
Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering.CRISPR J. 2023 Jun;6(3):243-260. doi: 10.1089/crispr.2022.0089. Epub 2023 May 23. CRISPR J. 2023. PMID: 37219969 Free PMC article.
-
A more efficient CRISPR-Cas12a variant derived from Lachnospiraceae bacterium MA2020.Mol Ther Nucleic Acids. 2021 Feb 18;24:40-53. doi: 10.1016/j.omtn.2021.02.012. eCollection 2021 Jun 4. Mol Ther Nucleic Acids. 2021. PMID: 33738137 Free PMC article.
-
The CRISPR-Cas12a Platform for Accurate Genome Editing, Gene Disruption, and Efficient Transgene Integration in Human Immune Cells.ACS Synth Biol. 2023 Feb 17;12(2):375-389. doi: 10.1021/acssynbio.2c00179. Epub 2023 Feb 7. ACS Synth Biol. 2023. PMID: 36750230 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources